The cyclopentenone (A2/J2) isoprostanes - Unique, highly reactive products of arachidonate peroxidation

Antioxidants and Redox Signaling

Volumn 7, Issue 1-2, 2005, Pages 210-220

  Milne, Ginger L ^a   Musiek, Erik S ^a   Morrow, Jason D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CARBONYL DERIVATIVE; CYCLOPENTENONE DERIVATIVE; DOCOSAHEXAENOIC ACID; FATTY ACID; FREE RADICAL; ISOPROSTANE A2; ISOPROSTANE DERIVATIVE; LINOLEIC ACID; PROSTAGLANDIN; PROSTAGLANDIN A2; PROSTAGLANDIN J2; PROSTAGLANDIN SYNTHASE; THIOL GROUP; UNCLASSIFIED DRUG; CARBON; CYCLOPENTANE DERIVATIVE; CYCLOPENTENONE; ICOSANOID; LEUKOTRIENE; LINOLENIC ACID; LIPID; PEROXIDE; PROSTAGLANDIN A;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; CHEMICAL STRUCTURE; DRUG SYNTHESIS; INFLAMMATION; MICHAEL ADDITION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PEROXIDATION; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; REVIEW; ANIMAL; CHEMICAL MODEL; CHEMISTRY; GAS CHROMATOGRAPHY; HUMAN; MASS FRAGMENTOGRAPHY; OXIDATION REDUCTION REACTION; TIME;

ANIMALIA;

ALPHA-LINOLENIC ACID; ANIMALS; ARACHIDONIC ACID; CARBON; CHROMATOGRAPHY, GAS; CYCLOPENTANES; DOCOSAHEXAENOIC ACIDS; EICOSANOIDS; FATTY ACIDS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; ISOPROSTANES; LEUKOTRIENES; LIPIDS; MODELS, CHEMICAL; OXIDATION-REDUCTION; PEROXIDES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS A; TIME FACTORS;

EID: 13244274900     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.210     Document Type: Review

References (71)

1. Alary J, Gueraud F, and Cravedi J-P. Fate of 4-hydroxynonenal in vivo: disposition and metabolic pathways. Mol Aspects Med 24: 177-187, 2003.
2. Ames BN. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 221: 1256-1264, 1983.
3. 2 with intracellular glutathione and enhancement of its antiproliferative activity by glutathione depletion. Cancer Res 50: 1879-1885, 1990.
4. 2. Biochemistry 29: 3760-3765, 1990.
5. Attallah A, Payakkapan W, Lee J, Carr A, and Brazelton E. PGA[prostaglandin A]. Fact, not artifact. Prostaglandins 5: 69-71, 1974.
6. Bamba H, Ota S, Kato A, Kawamoto C, and Fujiwara K. Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem Biophys Res Commun 273: 485-491, 2000.
7. 2 and the ligation of PPARγ. J Clin Invest 112: 945-955, 2003.
8. Bureau F, Desmet C, Melotte D, Jaspar F, Volanti C, Vanderplasschen A, Pastoret PP, Piette J, and Lekeux P. A proinflammatory role for the cyclopentenone prostaglandins at low micromolar concentrations: oxidative stress-induced extracellular signal-regulated kinase activation without NF-kappa B inhibition. J Immunol 168: 5318-5325, 2002.
9. Cagen LM, Pisano JJ, Ketley JN, Habig WH, and Jakoby WB. The conjugation of prostaglandin A1 and glutathione catalyzed by homogeneous glutathione S-transferases from human and rat liver. Biochim Biophys Acta 398: 205-208, 1975.
10. Carlson SE. Docosahexaenoic acid and arachidonic acid in infant development. Semin Neonatol 6: 437-449, 2001.
11. Cernuda-Morollon E, Pineda-Molina E, Canada FJ, and Perez-Sala D. 15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 276: 35530-35536, 2001.
12. Chen Y, Morrow JD, and Roberts LJ 2nd. Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J Biol Chem 274: 10863-10868, 1999.
13. 2) in vivo. Biochim Biophys Acta 1436: 550-556, 1999.
14. 2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 59: 2739-2746, 1999.
15. 2, to glutathione. Biochim Biophys Acta 1584: 37-45, 2002.
16. Daynes RA and Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2: 748-759, 2002.
17. Draper HH, Csallany AS, and Hadley M. Urinary aldehydes as indicators of lipid peroxidation in vivo. Free Radic Biol Med 29: 1071-1077, 2000.
18. Fam SS and Morrow JD. The isoprostanes: unique products of arachidonic acid oxidation - a review. Curr Med Chem 10: 1723-1740, 2003.
19. Fam SS, Murphey LJ, Terry ES, Zackert WE, Chen Y, Gao L, Pandalai S, Milne GL, Roberts LJ, Porter NA, Montine TJ, and Morrow JD. Formation of highly reactive A-ring and J-ring isoprostane-like compounds (A4/J4-neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 277: 36076-36084, 2002.
20. Fitzpatrick FA and Wynalda MA. Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. J Biol Chem 258: 11713-11718, 1983.
21. 2) in human THP-1 macrophages. Atherosclerosis 160: 11-20, 2002.
22. Fukushima M. Prostaglandin J2-anti-tumour and antiviral activities and the mechanisms involved. [erratum appears in Eicosanoids 4: 119, 1991]. Eicosanoids 3: 189-199, 1990.
23. Fukushima M. Prostaglandin J2-anti-tumour and antiviral activities and the mechanisms involved. [erratum appears in Eicosanoids 4: 119, 1991]. Eicosanoids 3: 189-199, 1990.
24. Fukushima M, Kato T, Ota K, Arai Y, Narumiya S, and Hayaishi O. 9-Deoxy-delta 9-prostaglandin D2, a prostaglandin D2 derivative with potent antineoplastic and weak smooth muscle-contracting activities. Biochem Biophys Res Commun 109: 626-633, 1982.
25. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, and Willoughby DA. Inducible cyclooxygenases may have anti-inflammatory properties. Nat Med 5: 698-701, 1999.
26. Gundlach H, Muller MJ, Kutchan TM, and Zenk MH. Jasmonic acid is a signal transducer in elicitor-induced plant cell cultures. Proc Natl Acad Sci U S A 89: 2389-2393, 1992.
27. Halliwell B and Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 186: 1-85, 1990.
28. Hamberg M and Samuelsson B. Prostaglandins in human seminal plasma. Prostaglandins and related factors 46. J Biol Chem 241: 257-263, 1966.
29. Harman D. The aging process. Proc Nat Acad Sci U S A 78: 7124-7128, 1981.
30. 2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway. J Immunol 168: 1372-1379, 2002.
31. Haslmayer P, Thalhammer T, Jager W, Aust S, Steiner G, Ensinger C, and Obrist P. The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-Delta12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. I J Oncol 21: 915-920, 2002.
32. 2 in human urine. J Biol Chem 263: 16619-16625, 1988.
33. Honn KV and Marnett LJ. Requirement of a reactive alpha,beta-unsaturated carbonyl for inhibition of tumor growth and induction of differentiation by "A" series prostaglandins. Biochem Biophys Res Commun 129: 34-40, 1985.
34. Hubatsch I, Ridderstrom M, and Mannervik B. Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation. Biochem J 330: 175-179, 1998.
35. 2), is efficiently conjugated with glutathione by human rat glutathione transferase A4-4. Chem Res Toxicol 15: 1114-1118, 2002.
36. Ianaro A, Ialenti A, Maffia P, Di Meglio P, Di Rosa M, and Santoro MG. Anti-inflammatory activity of 15-deoxy-delta12,14-PGJ2 and 2-cyclopenten-1-one: role of the heat shock response. Mol Pharmacol 64: 85-93, 2003.
37. Imbusch R and Mueller MJ. Formation of isoprostane F(2)-like compounds (phytoprostanes F(1)) from alpha-linolenic acid in plants. Free Radic Biol Med 28: 720-726, 2000.
38. Imbusch R and Mueller MJ. Analysis of oxidative stress and wound-inducible dinor isoprostanes F(1) (phytoprostanes F(1)) in plants. Plant Physiol 124: 1293-1304, 2000.
39. Jonsson HT, Middledtich BS, Schexnayder MA, and Desiderio DM. 11,15,19-Trihydroxy-9-ketoprosta-13-enoic acid and 11,15,19-trihydroxy-9- ketoprosta-5,13-dienoic acid in human seminal fluid. J Lipid Res 17: 1-6, 1976.
40. Jozkowicz A, Dulak J, Prager M, Nanobashvili J, Nigisch A, Winter B, Weigel G, and Huk I. Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-gamma-independent manner. Prostaglandins Other Lipid Mediat 66: 165-177, 2001.
41. Knight JA. Reactive oxygen species and the neurodegenerative disorders. Ann Clin Lab Sci 27: 11-25, 1997.
42. Koppal T, Petrova TV, and Van Eldik LJ. Cyclopentenone prostaglandin 15-deoxy-delta(12,14)-prostaglandin J(2) acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells. Brain Res 867: 115-121, 2000.
43. Lee TS, Tsai HL, and Chau LY. Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy-Delta (12,14)-prostaglandin J(2). J Biol Chem 278: 19325-19330, 2003.
44. Levonen AL, Dickinson DA, Moellering DR, Mulcahy RT, Forman HJ, and Darley-Usmar VM. Biphasic effects of 15-deoxy-delta(12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol 21:1846-1851, 2001.
45. Levonen A-L, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, Zanoni G, Morrow JD, and Darley-Usmar VM. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 378(Pt 2): 373-382, 2004.
46. Markesbery WR. Neuropathological criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 18: S13-S19, 1997.
47. Middledtich BS. PGA. Fact or artifact. Prostaglandins 9: 409-411, 1975.
48. 2t-isoprostane, is efficiently metabolized by HepG2 cells via conjugation with glutathione. Chem Res Toxicol 17: 17-25, 2004.
49. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ 2nd, and Morrow JD. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am J Pathol 155: 863-868, 1999.
50. Morrow JD, Tapper AR, Zackert WE, Yang J, Sanchez SC, Montine TJ, and Roberts LJ. Formation of novel isoprostane-like compounds from docosahexaenoic acid. Adv Exp Med Biol 469: 343-347, 1999.
51. Oliva JL, Perez-Sala D, Castrillo A, Martinez N, Canada FJ, Bosca L, and Rojas JM. The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras. Proc Nat Acad Sci U S A 100: 4772-4777, 2003.
52. Parchmann S and Mueller MJ. Evidence for the formation of dinor isoprostanes E1 from alpha-linolenic acid in plants. J Biol Chem 273: 32650-32655, 1998.
53. Parchmann S, Gundlach H, and Mueller MJ. Induction of 12-oxo-phytodienoic acid in wounded plants and elicited plant cell cultures. Plant Physiol 115: 1057-1064, 1997.
54. Parker J and Ankel H. Formation of a prostaglandin A2-glutathione conjugate in L1210 mouse leukemia cells. Biochem Pharmacol 43: 1053-1060, 1992.
55. Petrova TV, Akama KT, and Van Eldik LJ. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-delta12,14-prostaglandin J2. Proc Natl Acad Sci U S A 96: 4668-4673, 1999.
56. Reich EE, Zackert WE, Brame CJ, Chen Y, Roberts LJ 2nd, Hachey DL, Montine TJ, and Morrow JD. Formation of novel D-ring and E-ring isoprostane-like compounds (D4/E4-neuroprostanes) in vivo from docosahexaenoic acid. Biochemistry 39: 2376-2383, 2000.
57. Roberts LJ 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, and Morrow JD. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 273: 13605-13612, 1998.
58. Rossi A, Elia G, and Santoro MG. Inhibition of nuclear factor kappa B by prostaglandin A1: an effect associated with heat shock transcription factor activation. Proc Natl Acad Sci U S A 94: 746-750, 1997.
59. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, and Santoro MG. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403: 103-108, 2000.
60. Rovin BH, Lu L, and Cosio A. Cyclopentenone prostaglandins inhibit cytokine-induced NF-kappaB activation and chemokine production by human mesangial cells. J Am Soc Nephrol 12: 1659-1667, 2001.
61. Schneider C, Boeglin WE, and Brash AR. Enantiomeric separation of hydroxy eicosanoids by chiral column chromatography: effect of the alcohol modifier. Anal Biochem 287: 186-189, 2000.
62. Shibata T, Yamada T, Ishii T, Kumazawa S, Nakamura H, Masutani H, Yodoi J, and Uchida K. Thioredoxin as a molecular target of cyclopentenone prostaglandins. J Biol Chem 278: 26046-26054, 2003.
63. Skinner ER, Watt C, Besson JA, and Best PV. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 116: 717-725, 1993.
64. Southorn PA and Powis G. Free radicals in medicine. II. Involvement in human disease. Mayo Clinic Proc 63: 390-408, 1988.
65. Straus DS and Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21: 185-210, 2001.
66. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA 97: 4844-4849, 2000.
67. Thoma I, Loeffler C, Sinha AK, Gupta M, Krischke M, Steffan B, Roitsch T, and Mueller MJ. Cyclopentenone isoprostanes induced by reactive oxygen species trigger defense gene activation and phytoalexin accumulation in plants. Plant J 34: 363-375, 2003.
68. Xin X, Yang S, Kowalski J, and Gerritsen ME. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274: 9116-9121, 1999.
69. 2 isoprostane. J Org Chem 67: 4346-4351, 2002.
70. 2 isoprostane. J Org Chem 68: 6005-6010, 2003.
71. Zhang X, Wang JM, Gong WH, Mukaida N, and Young HA. Differential regulation of chemokine gene expression by 15-deoxy-delta 12,14 prostaglandin J2. J Immunol 166: 7104-7111, 2001.